Translational Medicine

Translational Medicine
Open Access

ISSN: 2161-1025

Geeta Shroff

Department of Stem Cell Therapy, Nutech Mediworld, India

Biography

Dr. Geeta Shroff has developed the technology to isolate human embryonic stem cells (hESC), culture them, prepare them for clinical application, and store them in ready-to-use form with a shelf life of six months. A graduate in medicine from the University of Delhi, Dr. Shroff did her post graduation in Gynecology & Obstetrics. A qualified IVF practitioner with vast knowledge and experience in embryology, she has been trained in all aspects of human stem cell culture, vitrification and thawing techniques. 

Publications

  • Short Communication   
    Translational Medicine 2015: Authorizing the efficiency of the Human Embryonic Stem Cell (hESC) therapy in cerebral palsy patients - Geeta Shroff - Nutech Mediworld
    Author(s): Geeta Shroff*

    Background: The present study evaluated the efficacy and safety of human embryonic somatic cell (hESC) therapy in patients with Cerebral Palsy (CP). Methods: This analysis comprised patients (30 days-18 years) with predictable identification of CP. The study consisted of four treatment phases (T1, T2, T3, T4) separated by gap phases. Efficacy of hESC therapy was evaluated supported Gross Motor Function Classification Scores Expanded and Revised (GMFCS-E & R; 1-good to 5-bad). Results: Ninety one patients were included and every one received hESC therapy in T1, 66 patients returned for T2, 38 patients for T3, and 15 patients for T4. General, 31.2% patients attained GMFCS-E & R score 1 throughout the study with dissimilar number of patients attaining GMFCS score 1 by the top of every single treatment phase (T1: 6 [6.6%]; T2: 7 [10.6%]; T3: 11 [28.9%]; and T4:.. View More»
    DOI: 10.35248/2161-1025.20.10.205

    Abstract HTML PDF

Top

https://sekillinickyazma.com.tr/